|
|
Article: PolyMedix Secures $10 Million Equity Line Facility with Dutchess Equity Fund, LP.
- Article from:
- Business Wire
- Article date:
- May 20, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PolyMedix to Receive up to $10.0 Million Over Three Years
RADNOR, Pa. -- PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has entered into an agreement with Dutchess Equity Fund, LP for up to $10 million of financing through an equity line facility. In accordance with the terms of the agreement, Dutchess has committed to purchase up to $10,000,000 of the Company's common stock over thirty-six months. While the per share price will be determined based on market prices in accordance with an agreed formula, the company will set its minimum ...
Related newspaper, magazine, and journal articles:
|
|
Article: PolyMedix Appoints Vice President of Drug Development.
PR Newswire;
November 10, 2005 ;
700+ words
... ... PHILADELPHIA, Nov. 10 /PRNewswire/ -- PolyMedix, Inc. announced today that it has appointed ... antibiotic and antifungal drugs. He comes to PolyMedix from Vicuron Pharmaceuticals, where ... Dr. Henkel will be leading all of PolyMedix's clinical, regulatory, and other ...
|
|